SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018706
Filing Date
2023-11-13
Accepted
2023-11-13 09:01:49
Documents
83
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q aeon-20230930x10q.htm   iXBRL 10-Q 2383288
2 EX-31.1 aeon-20230930xex31d1.htm EX-31.1 16340
3 EX-31.2 aeon-20230930xex31d2.htm EX-31.2 15940
4 EX-32.1 aeon-20230930xex32d1.htm EX-32.1 8654
5 EX-32.2 aeon-20230930xex32d2.htm EX-32.2 8106
  Complete submission text file 0001558370-23-018706.txt   10949147

Data Files

Seq Description Document Type Size
6 EX-101.SCH aeon-20230930.xsd EX-101.SCH 95343
7 EX-101.CAL aeon-20230930_cal.xml EX-101.CAL 42271
8 EX-101.DEF aeon-20230930_def.xml EX-101.DEF 388579
9 EX-101.LAB aeon-20230930_lab.xml EX-101.LAB 693258
10 EX-101.PRE aeon-20230930_pre.xml EX-101.PRE 576636
77 EXTRACTED XBRL INSTANCE DOCUMENT aeon-20230930x10q_htm.xml XML 2057723
Mailing Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614
Business Address 5 PARK PLAZA SUITE 1750 IRVINE CA 92614 (949) 354-6499
AEON Biopharma, Inc. (Filer) CIK: 0001837607 (see all company filings)

IRS No.: 853940478 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40021 | Film No.: 231395616
SIC: 2834 Pharmaceutical Preparations